Pieter Eichhorn

Research Interests

My work focuses on the identifying the mechanisms of resistance to targeted therapies in patients with identifiable standard of care alterations. Targeted therapy in cancer has markedly improved the outcome of this disease. However, despite survival gains provided by these therapies most responses remain transient as a result of primary or acquired resistance. Interestingly, the majority of molecular lesions that prime resistance to to these therapies result in the constitutive activation of targeted pathways through the repression of negative feedback loops. My lab focuses on these specific adaptive responses to MAPK and PI3K inhibitors in melanoma and breast cancer patients.

Education

• Honours Genetics The University of Western Ontario (1992 — 1996)

Companies

• Dean of Research Infrastructure Curtin University (2021)
• Associate Professor Curtin University (2018)
• Assistant Professor National University of Singapore (2013 — 2018)
• Principal Investigator Cancer Science Institute of Singapore (2013 — 2018)
• Instructor of Medicine Harvard Medical School (2010 — 2012)
• Assistant in Genetics Massachusetts General Hospital (2010 — 2012)
• Post. Doc VALL D'HEBRON INSTITUT D'ONCOLOGIA (2006 — 2010)
• Post.Doc NKI (2001 — 2006)
• Ph.D. University of Newcastle upon Tyne (1996 — 2000)

Publications

Journal Articles (Research)

2020

• Jaynes, P. W., P. V. Iyengar, S. K. L. Lui, T. Z. Tan, N. Vasilevski, S. C. E. Wright, G. Verdile, A. D. Jeyasekharan, and P. J. A. Eichhorn. 2020. "OTUD4 enhances TGFβ signalling through regulation of the TGFβ receptor complex." Scientific Reports 10 (1)
• Eichhorn, P. 2020. "c-Met activation leads to the establishment of a TGFβ-receptor regulatory network required for bladder cancer invasion." European Journal of Cancer 138

2019

• Teyra, J., A. U. Singer, F. W. Schmitges, P. Jaynes, S. Kit Leng Lui, M. J. Polyak, N. Fodil, J. R. Krieger, J. Tong, C. Schwerdtfeger, and 10 more contributors. 2019. "Structural and Functional Characterization of Ubiquitin Variant Inhibitors of USP15." Structure 27 (4): 590-605.e5.
• Li, B., J. Yan, T. Phyu, S. Fan, T. H. Chung, N. Mustafa, B. Lin, L. Wang, P. J. A. Eichhorn, B. C. Goh, and 3 more contributors. 2019. "MELK mediates the stability of EZH2 through site-specific phosphorylation in extranodal natural killer/ T-cell lymphoma." Blood 134 (23): 2046-2058.
• Sim, W. J., P. V. Iyengar, D. Lama, S. K. L. Lui, H. C. Ng, L. Haviv-Shapira, E. Domany, D. Kappei, T. Z. Tan, A. Saie, and 9 more contributors. 2019. "c-Met activation leads to the establishment of a TGFβ-receptor regulatory network in bladder cancer progression." Nature Communications 10 (1)

2018

• Saei, A., M. Palafox, T. Benoukraf, N. Kumari, P. W. Jaynes, P. V. Iyengar, E. Muñoz‑Couselo, P. Nuciforo, J. Cortés, C. Nötzel, and 10 more contributors. 2018. "Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies." Journal of Experimental Medicine 215 (7): 1913-1928.
• Saei, A., M. Palafox, T. Benoukraf, N. Kumari, P. Iyengar, Z. F. Bin Adam Isa, H. Yang, W. L. Tam, V. Serra, and P. Eichhorn. 2018. "Downregulation of USP28 confers poorer overall survival to melanoma patients and causes resistance to RAF inhibitors." Annals of Oncology 29
• Kumari, N., A. Saei, C. R. J. Lalith, V. Serra, S. Jha, and P. Eichhorn. 2018. "Identifying the oncogenic role of USP10 as the regulator of PTEN function in breast cancer." Annals of Oncology 29: iii10-iii11.

2017

• Kong, L. R., T. Z. Tan, W. R. Ong, C. Bi, H. Huynh, S. C. Lee, W. J. Chng, P. J. A. Eichhorn, and B. C. Goh. 2017. "Belinostat exerts antitumor cytotoxicity through the ubiquitin-proteasome pathway in lung squamous cell carcinoma." Molecular Oncology 11 (8): 965-980.

2016

• Nguyen, H. T., D. Andrejeva, R. Gupta, C. Choudhary, X. Hong, P. J. A. Eichhorn, A. C. Loya, and S. M. Cohen. 2016. "Deubiquitylating enzyme USP9x regulates hippo pathway activity by controlling angiomotin protein turnover." Cell Discovery 2

2015

• Iyengar, P. V., P. Jaynes, L. Rodon, D. Lama, K. P. Law, Y. P. Lim, C. Verma, J. Seoane, and P. J. A. Eichhorn. 2015. "USP15 regulates SMURF2 kinetics through C-lobe mediated deubiquitination." Scientific Reports 5

2013

• Serra, V., P. J. A. Eichhorn, C. García-García, Y. H. Ibrahim, L. Prudkin, G. Sánchez, O. Rodríguez, P. Antón, J. L. Parra, S. Marlow, and 7 more contributors. 2013. "RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer." Journal of Clinical Investigation 123 (6): 2551-2563.

2012

• Eichhorn, P. J. A., L. Rodón, A. Gonzàlez-Juncà, A. Dirac, M. Gili, E. Martínez-Sáez, C. Aura, I. Barba, V. Peg, A. Prat, and 7 more contributors. 2012. "USP15 stabilizes TGF-β2 receptor I and promotes oncogenesis through the activation of TGF-β2 signaling in glioblastoma." Nature Medicine 18 (3): 429-435.

2011

• Serra, V., M. Scaltriti, L. Prudkin, P. J. A. Eichhorn, Y. H. Ibrahim, S. Chandarlapaty, B. Markman, O. Rodriguez, M. Guzman, S. Rodriguez, and 7 more contributors. 2011. "PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer." Oncogene 30 (22): 2547-2557.
• Scaltriti, M., P. J. Eichhorn, J. Cortés, L. Prudkin, C. Aurac, J. Jiménez, S. Chandarlapaty, V. Serra, A. Prat, Y. H. Ibrahim, and 10 more contributors. 2011. "Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients." Proceedings of the National Academy of Sciences of the United States of America 108 (9): 3761-3766.

2008

• Eichhorn, P. J. A., M. Gili, M. Scaltriti, V. Serra, M. Guzman, W. Nijkamp, R. L. Beijersbergen, V. Valero, J. Seoane, R. Bernards, and 1 more contributors. 2008. "Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235." Cancer Research 68 (22): 9221-9230.
• Serra, V., B. Markman, M. Scaltriti, P. J. A. Eichhorn, V. Valero, M. Guzman, M. L. Botero, E. Llonch, F. Atzori, S. Di Cosimo, and 5 more contributors. 2008. "NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations." Cancer Research 68 (19): 8022-8030.

2007

• Eichhorn, P. J. A., M. P. Creyghton, K. Wilhelmsen, H. Van Dam, and R. Bernards. 2007. "A RNA interference screen identifies the protein phosphatase 2A subunit PR55γ as a stress-sensitive inhibitor of c-SRC." PLoS Genetics 3 (12): 2381-2394.

2006

• Creyghton, M. P., G. Roël, P. J. A. Eichhorn, L. C. Vredeveld, O. Destrée, and R. Bernards. 2006. "PR130 is a modulator of the Wnt-signaling cascade that counters repression of the antagonist Naked cuticle." Proceedings of the National Academy of Sciences of the United States of America 103 (14): 5397-5402.

2005

• Creyghton, M. P., G. Roël, P. J. A. Eichhorn, E. M. Hijmans, I. Maurer, O. Destrée, and R. Bernards. 2005. "PR72, a novel regulator of Wnt signaling required for Naked cuticle function." Genes and Development 19 (3): 376-386.

2004

• Tonkin, E. T., M. Smith, P. Eichhorn, S. Jones, B. Imamwerdi, S. Lindsay, M. Jackson, T. J. Wang, M. Ireland, J. Burn, and 3 more contributors. 2004. "A giant novel gene undergoing extensive alternative splicing is severed by a Cornelia de Lange-associated translocation breakpoint at 3q26.3." Human Genetics 115 (2): 139-148.